Global biosimilars market research report, by product (recombinant glycosylated proteins, recombinant non-glycosylated proteins and other), by application (Immune diseases, oncology, blood related disorders, other) manufacturing (contract, and in-house) - Forecast Till 2023

Market Scenario:
Biosimilars is a biological medical product which are identical copy of the original medical product. They are not generics nor treated like generic drugs. Biosimilars are derived from bacteria, plant, yeast and many other different process. Increasing incident of different diseases, strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars and increasing demand for the cheap medical products is responsible driving the global biosimilars market. On other hand lack of awareness and physician scepticism are the major restraining factor for the growth of the market.

Study Objectives global biosimilars market

- Detailed overview of global biosimilars market.
- Detail analysis of global biosimilars market with all possible segmentation and key player of market.
- Detailed analysis of the historical and forecasted market on the basis of factors like- price analysis, supply chain analysis, porters five force analysis etc.
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global biosimilars market.
- Detail analysis on the possible segments and sub segments of the market. And regional analysis of the market- North America, Europe, Asia Pacific and Middle East and Africa.
- Insights on the major countries/regions in which this industry is flourishing and to also identify the untapped regions which could be the potential markets in future.
The biosimilars market is expected to reach USD 16.97 Billion by 2023 from USD 3.35 Billion in 2016, at a CAGR of 26%.

Key Players for global biosimilars market

Pfizer Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Sandoz International GmbH (Germany), Celltrion, Inc. (South Korea), Astra Zeneca (UK), Amgen Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Biocon Ltd. (India), Dr. Reddy's Laboratories Ltd. (India), Novartis (Switzerland), Accord Healthcare (UK), Eli Lilly (US) and Samsung Bioepis (South Korea).

Segmentation

Global biosimilars market is segmented on the basis of product into recombinant glycosylated proteins, recombinant non-glycosylated proteins and other. Recombinant glycosylated proteins are further sub segmented into Monoclonal antibody (mAb) and EPO. Recombinant non-glycosylated proteins is sub segmented into insulin, growth hormones and other. On the basis of application the market is segmented into immune diseases, oncology, blood related disorders and other. On the basis of manufacturing, market is segmented into contract manufacturing and in-house manufacturing.

Regional Analysis

On regional basis, Europe has dominating market for the biosimilars market. Increasing prevalence of diseases and rising geriatric population has led to grow this market in Europe. North America has second leading market followed by Asia Pacific. Asia Pacific biosimilars market is growing at a CAGR of 27.8 % during 2017-2023.

Market Assessment
The report for global biosimilars market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

**Intended Audience**

- Research and Development (R&D) Companies
- Biopharmaceutical drug manufacturers
- Biotechnology, biopharmaceutical, and pharmaceutical companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
- Government and Independent Research Laboratories
- Contract Research Organizations (CROs)

**Contents:**

1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRANTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS
4.1 PORTER'S FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY

5. GLOBAL BIOSIMILARS MARKET, BY PRODUCT
5.1 RECOMBINANT GLYCOSYLATED PROTEINS
5.1.1 MONOCLONAL ANTIBODY
5.1.2 EPO
5.2 RECOMBINANT NON-GLYCOSYLATED PROTEINS
5.2.1 INSULIN
5.2.2 GROWTH HORMONES
5.2.3 OTHER
5.3 OTHER

6. GLOBAL BIOSIMILARS MARKET, BY APPLICATION
6.1 IMMUNE DISEASES
6.2 ONCOLOGY
6.3 BLOOD RELATED DISORDERS
6.4 OTHER

7. GLOBAL BIOSIMILARS MARKET, BY MANUFACTURING
7.1 CONTRACT MANUFACTURING
7.2 IN-HOUSE MANUFACTURING

8. GLOBAL PAIN MANAGEMENT DEVICES MARKET, BY REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 WESTERN EUROPE
8.3.1.1 GERMANY
8.3.1.2 FRANCE
8.3.1.3 ITALY
8.3.1.3 SPAIN
8.3.1.5 UK
8.3.1.6 REST OF WESTERN EUROPE
8.3.2 EASTERN EUROPE
8.4 ASIA
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 AUSTRALIA
8.4.5 REPUBLIC OF KOREA
8.5 REST OF ASIA-PACIFIC
8.6 MIDDLE EAST & AFRICA

9. COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
9.1.1 STRATEGIC PARTNERSHIP
9.1.2 MERGER & ACQUISITION

10 COMPANY PROFILE
10.1 PFIZER INC.
10.1.1 OVERVIEW
10.1.2 PRODUCT OVERVIEW
10.1.3 FINANCIALS
10.1.4 KEY DEVELOPMENTS
10.2 TEVA PHARMACEUTICALS INDUSTRIES LTD
10.2.1 OVERVIEW
10.2.2 PRODUCT OVERVIEW
10.2.3 FINANCIALS
10.2.4 KEY DEVELOPMENTS
10.3 SANDOZ INTERNATIONAL GMBH
10.3.1 OVERVIEW
10.3.2 PRODUCT OVERVIEW
10.3.3 FINANCIALS
10.3.4 STRATEGY
10.3.5 KEY DEVELOPMENT
10.4 CELLTRION, INC.
10.4.1 OVERVIEW
10.4.2 PRODUCT OVERVIEW
10.4.3 FINANCIALS
10.4.4 KEY DEVELOPMENTS
10.5 ASTRA ZENECA
10.5.1 OVERVIEW
10.5.2 PRODUCT OVERVIEW
10.5.3 FINANCIALS
10.5.4 KEY DEVELOPMENTS  
10.6 OTHERS  
11 CONCLUSION  
11.1 KEY FINDINGS  
11.1.1 FROM CEO’S VIEWPOINT  
11.1.2 UNMET NEEDS OF THE MARKET  
11.2 KEY COMPANIES TO WATCH  
11.3 PREDICTION OF INDUSTRY  
12 APPENDIX